Drug intelligence / Profile preview

Shenghuo HuoXue

Development stage: Unknown
Lead developer: China Resources Kunming Shenghuo Pharmaceutical
Administration: Injection

Overview

Shenghuo HuoXue is a Traditional Chinese Medicine (TCM) formulation administered as an injection. It is primarily indicated for cardiovascular conditions and also for circulatory and pain relief. The drug was originally developed by Kunming Shenghuo Pharmaceutical, a company later acquired by CR Sanjiu Medical & Pharmaceutical, which now leverages this product within its TCM portfolio.

Brand names: Shenghuo HuoXue Injection

Beyond the preview

Go deeper on Shenghuo HuoXue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenghuo HuoXue.

Explore the full profile